Below are some monoclonal antibodies that have already been introduced to modern medicine. These have been directly quoted
from another source.
· Omalizumab (Xolair®). Binds to IgE thus preventing IgE from binding to mast cells. Shows promise against allergic asthma.
· Bexxar® (tositumomab). This is a conjugate of a monoclonal antibody against CD20 and the radioactive isotope iodine-131
(131I). It, too, is designed as a treatment for lymphoma. Although both Bexxar® and Zevalin® kill normal B cells, they don't
harm the B-cell precursors because these do not express CD20. So, in time, the precursors can repopulate the body with healthy
· LymphoCide. Binds to CD22, a molecule found on some B-cell leukemia.
· Abciximab (ReoPro®). Inhibits the clumping of platelets by binding the receptors on their surface that normally are
linked by fibrinogen. Helpful in preventing reclogging of the coronary arteries in patients who have undergone angioplasty.